ARIScience

What ARIScience does

ARIScience is a privately held, Wayland, Massachusetts-based biotechnology company that operates an AI-driven drug discovery platform targeting infectious, neurodegenerative, inflammatory, and — most recently — oncological diseases. The company's core offering is the AI+QQ process, a unified in silico methodology that combines artificial intelligence, quantum chemistry, computer vision, and biochemistry to predict and design small molecule compounds capable of directly, allosterically, or formatively interrupting target proteins in disease pathways. The platform is supported by two proprietary technology assets: BioTD, an HPC-driven in silico platform for molecular simulation, alignment, DFT-based frequency analysis, and functional group identification; and ARICore, a high-performance software library providing mathematical computations, graph algorithms, point cloud manipulation, and standard supervised learning routines for predictive analytics.

ARIScience runs a services and research-collaboration business model. It generates revenue through government research contracts (notably a completed BARDA countermeasure contract, April 2023 – October 2024), fee-for-service engagements with academic institutions such as the University of North Dakota, co-development partnerships with clinical and translational organizations (most recently MSK Therapeutics Accelerator at Memorial Sloan Kettering Cancer Center for metastasis-targeting therapeutics), and the prospective licensing of internally developed drug candidates. Pricing is not publicly disclosed; engagements are negotiated directly through the company's website and phone line. Customer mix is concentrated across federal agencies, academic medical centers, and pharmaceutical collaborators, with the MSK partnership signaling the company's first move into oncology co-development.

Name

ARIScience

Legal name

ARIScience

Website

https://ariscience.com

Company type

Private

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Computational Drug Discovery

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Software Publishers (5132)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Computer Programming Services (7371)

akta.pro primary industry

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

akta.pro secondary industries

In Silico / Computational Toxicology & PK/PD Modeling (HLAGAFAM), Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA)

Keywords

• AI drug discovery
• Small molecule therapeutics
• Quantum chemistry platform
• In silico drug design
• Computational biotechnology

Headquarters

HQ city

Wayland

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations

Revenue model

1. Government Research Contracts: ARIScience secured a BARDA advanced protein impact via small molecule research contract (April 2023), successfully completed in October 2024. Government contracts represent a significant revenue stream for countermeasure development.
2. Research Collaboration Services: Fee-for-service research engagements with academic institutions (University of North Dakota) and pharmaceutical partners. Clients engage ARIScience to analyze proteins and find cognate small molecule candidates for interrupting disease pathways.
3. Drug Pipeline Development: Proprietary drug discovery pipeline targeting infectious diseases, neurodegenerative diseases, and inflammatory conditions. Potential future revenue through licensing, co-development partnerships, or acquisition.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

ARIScience provides computational drug discovery services using its proprietary AI+QQ (Artificial Intelligence + Quantum Chemistry) process to design small molecule compounds that interrupt disease-related proteins. The company delivers end-to-end drug discovery spanning in silico prediction, synthesis and in vitro assays, iteration and optimization, in vivo confirmation, and First in Human trial preparation, supported by its BioTD HPC platform and ARICore software library.

Product overview

ARIScience offers a unified AI+QQ (AI + Quantum Chemistry) drug discovery platform that combines AI, quantum chemistry, computer vision, and biochemistry. The portfolio centers on the AI+QQ Process as the core methodology, supported by two technology assets: BioTD (an in silico HPC platform for molecular simulation and optimization) and ARICore (a high-performance software library for mathematical computations). The company provides end-to-end drug discovery services from in silico compound prediction through synthesis, in vitro/in vivo testing, to First in Human trials. The AI+QQ Process orchestrates both BioTD and ARICore capabilities to discover small molecule inhibitors and stimulators for treating infectious diseases, neurodegenerative disorders, and inflammatory conditions.

Differentiator

Problem solved

Functional benefit

Products and services

• AI+QQ Drug Discovery Process ARIScience's core proprietary methodology that unifies AI, quantum chemistry, computer vision, and biochemistry to design and discover small molecule compounds that directly, allosterically, or formatively interrupt target proteins implicated in infectious, neurodegenerative, and inflammatory diseases. Delivered as an end-to-end service spanning ideation/simulation, synthesis/in vitro assays, iteration/optimization, in vivo confirmation, and First in Human trial preparation.
• BioTD In silico platform leveraging High-Performance Computing to simulate complex biological systems and predict small molecule behavior. Features include molecular alignment, charge distribution identification, H atom insertion, DFT-based frequency analysis, functional group identification, molecular symmetry detection, molecular rendering without GPUs, and quantum chemistry-driven molecular optimization. Supports the AI+QQ process without requiring in-house computational setup.
• ARICore High-performance software library delivering fast, low-footprint mathematical computations and AI/statistical methods. Includes 1D/2D/3D integrations, root discovery, directed/undirected graph algorithms, point cloud manipulation, AI methods (Random Forest, Logistic Regression, SVM, Naive Bayes), Fourier transforms, and specialized math structures (KD-Trees, sparse matrices, coordinate transformation matrices). Optimized for HPC environments.
• Drug Discovery Services End-to-end small molecule drug discovery services for clients including pharmaceutical companies, government agencies (BARDA), and academic institutions. Spans ideation and simulation (in silico), synthesis and in vitro assays (FRET, ITC, SPR, antiviral assays), iteration and optimization, in vivo confirmation (murine models), and First in Human trial preparation including IND applications. Delivered via the AI+QQ process and BioTD/ARICore platforms.

Quantifiable outcome

• 100% validation rate for AI+QQ predictions tested in wet labs
• +1 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature3 records

Partnerships

Three partnerships are on record, tiered core and supporting.

• MSK Therapeutics Accelerator (Memorial Sloan Kettering Cancer Center)coreStrategic or Co-development Partner · 26 March 2026Collaboration to advance novel precision small molecule therapeutic candidates targeting metastasis. ARIScience gains access to MSK's drug development resources and translational expertise for preclinical testing. Combines ARIScience's AI, quantum chemistry, and computer vision with MSK's clinical and scientific resources for co-development of precision therapeutics for cancer patients.
• BARDA (Biomedical Advanced Research and Development Authority)coreStrategic or Co-development Partner · 1 April 2023Advanced protein impact via small molecule research contract awarded April 2023, successfully completed October 2024. BARDA (US government agency under HHS/ASPR) provided funding and oversight for medical countermeasure development using ARIScience's AI+QQ platform.
• University of North Dakota (UND)supportingStrategic or Co-development Partner · 31 July 2022Research collaboration agreement using UND Computational Research Center's high performance computing (HPC) system to further ARIScience's SARS-CoV-2 protein interruption research. UND provides HPC infrastructure while ARIScience contributes AI+QQ methodology.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• BenevolentAI: AI-driven drug discovery company applying ML to biomedical knowledge graphs for target identification. Comparable in pharma partnership model and AI-driven small molecule discovery.
• XtalPi: AI + quantum physics-based drug discovery platform combining computational chemistry with robotics. Closest peer in combining AI with quantum-level simulation for small molecule design.
• Exscientia: AI-driven precision medicine company focused on small molecule drug discovery with multiple clinical-stage assets. Direct competitor in pharma partnerships and pipeline development.
• Atomwise: AI small molecule drug discovery platform using convolutional neural networks to predict binding. Comparable in B2B pharma partnership model and small molecule focus; ARIScience's quantum chemistry angle is the key differentiator.
• Schrödinger: Public computational drug discovery platform combining physics-based simulation with ML for small molecule design. Most directly comparable to ARIScience's AI+QQ approach given both use quantum chemistry alongside AI; significantly larger and better-capitalized.
• Recursion: AI-driven drug discovery combining high-throughput biology with ML. Direct competitor in AI-enabled target identification and small molecule discovery, with broader imaging-led approach.
• Insilico Medicine: AI-driven drug discovery company with end-to-end pipeline from target identification to clinical candidates. Competes directly in small molecule discovery using AI/ML; serves similar pharma and academic customers.

Broad incumbents

• Isomorphic Labs: Alphabet-owned AI drug discovery company leveraging DeepMind's protein folding and computational chemistry capabilities. Adjacent but more capitalized competitor in computational/AI-driven drug design.
• Charles River Laboratories: Large CRO offering drug discovery services including in silico, in vitro, and in vivo capabilities. Comparable in serving pharma customers with end-to-end discovery services, though ARIScience's AI+QQ is a more specialized platform.

Emerging players

• Iambic Therapeutics: Emerging AI-driven drug discovery platform combining physics-based modeling with neural networks. Comparable in combining quantum physics with AI for small molecule discovery, similar early-stage profile.

Market position

Strengths3 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ARIScience